Trials / Withdrawn
WithdrawnNCT03886402
Adipose-derived SVF for Treatment of Erectile Dysfunction (ED)
Use of Autologous Adipose-derived Stromal Vascular Fraction to Treat Erectile Dysfunction - A Safety and Feasibility Study
- Status
- Withdrawn
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 0 (actual)
- Sponsor
- GID BIO, Inc. · Industry
- Sex
- Male
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Accepted
Summary
This study will examine the safety and feasibility of a single injection of autologous adipose-derived stromal vascular fraction to treat erectile dysfunction.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DEVICE | GID SVF-2 | Treatment of erectile dysfunction with the subjects own cells |
Timeline
- Start date
- 2021-10-01
- Primary completion
- 2022-10-01
- Completion
- 2022-10-01
- First posted
- 2019-03-22
- Last updated
- 2025-04-24
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated device study
Source: ClinicalTrials.gov record NCT03886402. Inclusion in this directory is not an endorsement.